脂蛋白(a)是一种普遍存在但却未得到充分认识的心血管疾病风险因素。 - Suppr

Suppr

超能文献

Lipoprotein(a) is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease.

作者信息

Rendler Jacob, Murphy Mia, Yeang Calvin

机构信息

Division of Cardiology, Department of Medicine, UC San Diego, La Jolla, California, United States of America.

出版信息

Health Care Curr Rev. 2024;12(2). Epub 2024 Mar 12.

PMID:38525410

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10959503/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/248d/10959503/52e1a85ca107/nihms-1969472-f0001.jpg

相似文献

Lipoprotein(a) is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease.

Health Care Curr Rev. 2024;12(2). Epub 2024 Mar 12.

Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?

J Clin Med. 2022 Jul 28;11(15):4380. doi: 10.3390/jcm11154380.

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.

Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14.

Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?

Womens Health Issues. 1992 Summer;2(2):102-11; discussion 111-3. doi: 10.1016/s1049-3867(05)80278-6.

Should we Consider Lipoprotein (a) in Cardiovascular Disease Risk Assessment in Patients with Familial Hypercholesterolaemia?

Curr Pharm Des. 2018;24(31):3665-3671. doi: 10.2174/1381612824666181010150958.

Improving Cardiovascular Risk in Postmenopausal Women with an (-)-Epicatechin-Based Nutraceutical: A Randomly Assigned, Double-Blind vs. Placebo, Proof-of-Concept Trial.

J Clin Med. 2023 Dec 29;13(1):195. doi: 10.3390/jcm13010195.

A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study.

Circulation. 1994 Oct;90(4):1688-95. doi: 10.1161/01.cir.90.4.1688.

[Underrecognized peripheral arterial disease in patients with acute coronary syndrome: prevalence of traditional and emergent cardiovascular risk factors].

Rev Esp Cardiol. 2005 Dec;58(12):1403-10.

Circulating Metabolites and Cardiovascular Disease in Asians with Chronic Kidney Disease.

Cardiorenal Med. 2023;13(1):301-309. doi: 10.1159/000533741. Epub 2023 Sep 5.

High levels of HDL cholesterol do not predict protection from cardiovascular disease in women.

Prev Cardiol. 2007 Summer;10(3):125-7. doi: 10.1111/j.1520-037x.2007.05858.x.

引用本文的文献

Impact of severe dyslipidemia on renal function: A cross-sectional study.

Medicine (Baltimore). 2025 Aug 29;104(35):e44131. doi: 10.1097/MD.0000000000044131.

Prevalence and Correlates of Lipoprotein(a) Testing in a Diverse Cohort of U.S. Adults.

JACC Adv. 2025 May 30;4(6 Pt 1):101826. doi: 10.1016/j.jacadv.2025.101826.

Lipoprotein(a) and coronary artery disease: The need for universal screening - A case-based review.

Am Heart J Plus. 2025 Jun 1;56:100560. doi: 10.1016/j.ahjo.2025.100560. eCollection 2025 Aug.

Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels.

Ann Transl Med. 2025 Apr 30;13(2):11. doi: 10.21037/atm-25-40. Epub 2025 Apr 29.

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications.

Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16469.

Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications.

J Clin Med. 2025 Apr 25;14(9):2990. doi: 10.3390/jcm14092990.

Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.

Circulation. 2025 Jan 28;151(4):312-321. doi: 10.1161/CIRCULATIONAHA.124.069556. Epub 2024 Nov 4.

本文引用的文献

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.

JAMA. 2023 Dec 5;330(21):2075-2083. doi: 10.1001/jama.2023.21835.

Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States.

J Am Heart Assoc. 2023 Sep 19;12(18):e031255. doi: 10.1161/JAHA.123.031255. Epub 2023 Sep 13.

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.

JAMA. 2023 Sep 19;330(11):1042-1053. doi: 10.1001/jama.2023.16503.

Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes.

Am J Prev Cardiol. 2023 Mar 1;14:100478. doi: 10.1016/j.ajpc.2023.100478. eCollection 2023 Jun.

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6.

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

J Clin Lipidol. 2022 Sep-Oct;16(5):e77-e95. doi: 10.1016/j.jacl.2022.08.007. Epub 2022 Aug 26.

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.

JAMA. 2022 May 3;327(17):1679-1687. doi: 10.1001/jama.2022.5050.

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.

Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14.

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.

Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016. Epub 2021 Mar 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验